Soluble (s) CD14 and Plasmatic Lipopolysaccharides (LPS) in Patients with Chronic Hepatitis C Before and After Treatment with Interferon (IFN)-α

References

• Jirillo E., Greco B., Caradonna L., et al. Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol. Immunotoxicol 1995; 17: 347
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock H WL, Ulewitch R J. CD14: cell surface receptor and differentation marker. Immunol. Today 1993; 14: 121
   PubMedGoogle Scholar
• Wright S. D., Ramos R. A., Tobias P. S., et al. CD14, receptor for lipopolysaccharide (LPS) and LPS-Binding Protein. Science 1990; 249: 1431
   PubMed Web of Science ®Google Scholar
• Morrison D. C., Danner R. L., Dinarello C. A., et al. Bacterial endotoxins and pathogenesis of gram-negative infections. Current status and future directions. J. Endotoxin Res. 1994; 1: 71
   Google Scholar
• Osnes L TN, Westvik A B, Ovstebo R., et al. Lipopolysaccharide activation of human monocytes by CD14 result in a coordinated synthesis of tissue factor, TNF-α and IL-6. J. Endotoxin Res 1995; 2: 27
   Google Scholar
• Bazil V., Strominger J. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 1991; 147: 1567
   PubMed Web of Science ®Google Scholar
• Bufler P., Stieger G., Schuchmann M., et al. Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants. Eur. J. Immunol. 1986; 16: 1583
   PubMedGoogle Scholar
• Grunwald V., Kruger C., Westermann J., et al. An enzyme-linked immunosorbent assay for the quantification of solubized CD14 in biological fluids. J. Immunol. Methods 1992; 155: 225
   PubMed Web of Science ®Google Scholar
• Hallot A., Rong G. W., Silver J., et al. Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J. Immunol. 1993; 151: 1500
   PubMed Web of Science ®Google Scholar
• Pugin J., Schurer-Maly C. C., Leturq D., et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc. Natl. Acad. Sci, USA 1993; 90: 2744
   PubMed Web of Science ®Google Scholar
• Zhang J-K., Morrison T K, Falk M C., et al. Characterization of the binding of soluble CD14 to human endothelial cells and mechanisms for CD14-dependent cell activation by IPS. J. Endotoxin Res. 1996; 3: 307
   Google Scholar
• Rabinovik R., Neville L. F., Feverstein G. Current understanding of sepsis:criticism and proposal. J. Endotoxin Res. 1995; 2: 163
   Google Scholar
• Oesterreicher C., Pfeffel F., Peterman D., et al. Increased in vitro production and serum levels of the soluble lipolysaccharide receptor sCD14 in liver disease. J. Hepatol. 1995; 23: 396
   PubMed Web of Science ®Google Scholar
• Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 1968; 21(suppl. 97)77
   PubMed Web of Science ®Google Scholar
• Antonaci S., Tortorella C., De Simone C., et al. Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes. Intern. Rev. Immunol. 1990; 6: 237
   PubMedGoogle Scholar
• Cromogenix Laboratory instruction: S-2423. Determination of gram-negative bacterial endotoxins in water and in solutions for parenteral administration
   Google Scholar
• Merchant A., Duchow J., Delville J-P, et al. Lipopolysaccharide induces up-regulation of CD14 molecule on monocytes in human whole blood. Eur. J. Immunol. 1992; 22: 1663
   PubMed Web of Science ®Google Scholar
• Landmann R., Wesp M., Ludwig C., et al. Recombinant interferon-γ up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients. Cancer Immunol. Immunother. 1990; 31: 292
   PubMed Web of Science ®Google Scholar
• Steinman G G., Rosenkamer F., Leitz G. Clinical experiences with interferon-α and interferon-y. Int. Rev. Exp. Pathol. 1993; 348: 193
   Google Scholar
• Dianziani F. Interferon toxicity. A mechanistic view trend. Exp. Clin. Med. 1995; 4: 397
   Google Scholar
• Jirillo E., Greco B., Caradonna L., et al. Immunological effects following administration of interferon-α in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol. Immunotoxicol. 1996; 18: 335
   Web of Science ®Google Scholar
• Jack R S., Grunwald V., Stelter F., et al. Both membrane-bound and soluble forms of CD14 bind to gram-negative bacteria. Eur. J. Immunol. 1995; 25: 604
   PubMed Web of Science ®Google Scholar
• Mailman E., Vasselon T., Kelley M., et al. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 1996; 156: 4384
   PubMed Web of Science ®Google Scholar
• Giannelli G., Piazzolla G., Tortorella C., et al. Neutrophil oxidative responsiveness in chronic hepatitis C. Med. Sci. Res. 1996; 24: 99
   Google Scholar
• Piazzolla G., Giannelli G., Antonelli G., et al. Effects of interferon-a treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class antigen expression in patients with chronic hepatitis C. Immunopharmacol. Immunotoxicol. 1996; 18: 529
   PubMed Web of Science ®Google Scholar
• Nockker W A., Wigand R., Schoeppe W., et al. Elevated levels of soluble CD14 in serum of patients with Systemic Lupus Erythematosus. Clin. Exp. Immunol. 1994; 96: 15
   PubMed Web of Science ®Google Scholar
• Nockker W A., Bergmann L., Scherberich J. E. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HCV-infected patients. Clin. Exp. Immunol. 1994; 98: 369
   PubMed Web of Science ®Google Scholar
• Kruger C., Shutt C., Obertacke V. Serum CD14 levels in polytraumatized and severely burned patients. Clin. Exp. Immunol. 1991; 85: 297
   PubMed Web of Science ®Google Scholar